SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPorvair Regulatory News (PRV)

Share Price Information for Porvair (PRV)

Share Price is delayed by 15 minutes
Get Live Data
830.00    14.00 (1.72%)
Bid:
824.00
Ask:
828.00
Spread: 4.00 (0.485%)
Market Cap: £382.60m
PRV Live PriceLast checked at - London Stock Exchange

Intraday Porvair Share Chart

Trading Update and Covid-19 Statement

8 Apr 2020 07:00

RNS Number : 1263J
Porvair PLC
08 April 2020
 

For immediate release 8 April 2020

 

Porvair plc

("Porvair" or the "Group")

 

Trading Update and Covid-19 Statement

Porvair plc ("Porvair" or "the Group"), the specialist filtration and environmental technology group, today issues a trading update and comment on COVID-19.

The overriding priority for Porvair management teams over the last few weeks has been the wellbeing of staff and their families. Health and safety guidelines for each country are being followed and physical distancing at work is being observed. Staff in China remained on full pay throughout a seven week shut-down and are now all back at work. Where staff members elsewhere in the Group have needed to self-isolate similar arrangements have been made.

Porvair is doing what it can to help governments and health services. We are supplying filter components for several of the consortia now building ventilator and breathing apparatus: one in France; one in Sweden; three in the US; and the Mercedes AMG/Formula 1 consortium in the UK. Porvair is supplying consumables for dozens of US testing laboratories, including the Mayo Clinic; is producing millions of pipette tips for COVID-19 testing kits; and thousands of filters for Diagnostics in the Real World. Shifts have been added to produce chromatography bed supports and pharmaceutical grade water filters. The Board anticipates further programmes will emerge as the crisis continues. Whilst these orders are relatively small they illustrate the capabilities and commitment of our staff.

In financial terms, the impact on the Group will depend on the duration of the COVID-19 pandemic and on the severity of its economic consequences. The Board of Porvair has considered various outlook scenarios, stress testing the Group for different levels of challenge, plant by plant. The Group has a strong balance sheet and is expected to be both profitable and modestly cash generative through the balance of the year in all but the most pessimistic scenarios. The Board does not believe it needs to change its final dividend recommendation.

In its outlook statement dated 31 January 2020 the Group noted its positive exposure to global growth trends including tighter environmental regulations; growth in analytical science; the expansion of air travel; the replacement of plastic by aluminium and the drive for manufacturing process efficiency. Looking to 2021 and beyond the Group expects these trends to continue. Indeed, 2020 has started well with revenues ahead of the prior year in the four months to the end of March. All plants are currently open and April is busy. However, there will no doubt be disruption during the rest of the year. Demand, in sectors including aviation, automotive and industrial manufacturing, is likely to decline. Other sectors, mainly in the Laboratory division, are expected to remain busy. As we wait to see how the economic consequences of COVID 19 develop, the Board therefore considers it prudent to withdraw guidance until the outlook is more certain.

Should the situation change significantly, the Group will issue a further update at its AGM on 21 April 2020.

For further information, please contact:

Porvair plc

 

01553 765 500

Ben Stocks, Group Chief Executive

Chris Tyler, Group Finance Director

 

 

Buchanan Communications

 

0207 466 5000

Charles Ryland / Steph Watson

 

 

 

Notes to editors

 

Porvair plc

Porvair is a group of specialist filtration and environmental technology businesses. Its businesses design and manufacture a range of bespoke consumable filtration products that are used in a range of niche filtration markets. It operates in three divisions: Aerospace & Industrial; Laboratory; and Metal Melt Quality.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAKLXESLEEFA
Date   Source Headline
1st Mar 20239:30 amRNSTotal Voting Rights
2nd Feb 20235:42 pmRNSGrant of LTSP awards
30th Jan 20237:00 amRNSResults for the year ended 30 November 2022
17th Jan 20234:40 pmRNSSecond Price Monitoring Extn
17th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Dec 20227:00 amRNSTrading Update, Notice of Results and Board Change
1st Dec 20224:00 pmRNSDirector/PDMR Shareholding
1st Dec 202210:00 amRNSTotal Voting Rights
29th Nov 20224:35 pmRNSPrice Monitoring Extension
1st Nov 20224:00 pmRNSBlock listing Interim Review
1st Nov 20227:00 amRNSTotal Voting Rights
27th Oct 20229:30 amRNSDirector declaration and resignation
12th Oct 20224:26 pmRNSDirector/PDMR Shareholding
5th Oct 20225:30 pmRNSHolding(s) in Company
5th Oct 20225:30 pmRNSHolding(s) in Company
4th Oct 20227:00 amRNSTrading Update-Ahead of Expectations
22nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:36 pmRNSPrice Monitoring Extension
20th Sep 20224:41 pmRNSSecond Price Monitoring Extn
20th Sep 20224:36 pmRNSPrice Monitoring Extension
13th Sep 20227:00 amRNSNine Month Trading Update
9th Sep 20224:40 pmRNSSecond Price Monitoring Extn
9th Sep 20224:35 pmRNSPrice Monitoring Extension
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:35 pmRNSPrice Monitoring Extension
7th Sep 20226:05 pmRNSDirector/PDMR Shareholding
6th Sep 20224:40 pmRNSHolding(s) in Company
2nd Sep 20223:06 pmRNSHolding(s) in Company
10th Aug 20224:40 pmRNSSecond Price Monitoring Extn
10th Aug 20224:36 pmRNSPrice Monitoring Extension
9th Aug 20224:36 pmRNSPrice Monitoring Extension
8th Jul 20227:00 amRNSDirector Declaration
5th Jul 20224:35 pmRNSPrice Monitoring Extension
4th Jul 20227:00 amRNSHalf Year Results 2022
30th Jun 20222:15 pmRNSDirector/PDMR Shareholding
29th Apr 20224:41 pmRNSSecond Price Monitoring Extn
29th Apr 20224:36 pmRNSPrice Monitoring Extension
28th Apr 20227:00 amRNSDirector/PDMR Shareholding
14th Apr 20221:42 pmRNSAGM resolutions
14th Apr 20227:00 amRNSAGM Trading Update
11th Mar 20224:41 pmRNSSecond Price Monitoring Extn
11th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20224:35 pmRNSPrice Monitoring Extension
28th Feb 20227:00 amRNSBlock listing Interim Review
28th Feb 20227:00 amRNSTotal Voting Rights
4th Feb 20223:00 pmRNSDirector/PDMR Shareholding
4th Feb 202212:20 pmRNSGrant of LTSP awards
3rd Feb 202211:27 amRNSDirector/PDMR Shareholding
31st Jan 20227:00 amRNSResults for the year ended 30 November 2021
14th Dec 202112:25 pmRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.